IRBM to collaborate with MSD to develop peptides against coronavirus
Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
21st July 2020, Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2. The parties will collaborate in hit to lead optimization and preclinical drug development to rapidly advance selected candidates towards the clinic.
We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
Ready to race? Come talk to us at BIO Digital from 8-12th June in our virtual drug discovery pavilion. IRBM are an innovative research organization working across all aspects of drug discovery and early development for different modalities – small molecule, peptides and antibodies.
IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.